ClinicalTrials.gg
Not yet recruitingNCT06048874Updated Sep 22, 2023

FNB in ACL Recon Under SA

An interventional study of Sono-guided injection and Ropivacaine injection in Anterior Cruciate Ligament Rupture and Femoral Nerve Block, sponsored by Chuncheon Sacred Heart Hospital. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Chuncheon Sacred Heart Hospital · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Study summary

The investigators will compare the results of sono-guided femoral nerve block in arthroscopic surgery for anterior cruciate ligament reconstruction under spinal anesthesia.

Read the detailed description

This study is a randomized controlled trial of 100 patients, who underwent history taking, physical examinations, x-rays, and MRI or ultrasonography, and were diagnosed with anterior cruciate ligament rupture from september 2023 to august 2028. The 100 patients will be assigned to Group I (with femoral nerve block) or Group II (without femoral nerve block) under double-blinded randomization. The randomization will be performed by an independent nurse using a computerized random sequence generator. The operators who participated in the procedure will be blinded to the participant's information. Both group will undergo spinal anesthesia for arthroscopic anterior cruciate ligament reconstruction. After anesthesia, sono-guided femoral nerve block will be performed. The injection for group1 is 20 mL ropivacaine and for groupII is 20 mL 0.9% saline. A visual analog scale (VAS) for pain will be recorded 1, 3, 6, 12, 18, 24, 36, 48 hours after the operation. VAS scores range from 0 to 10, with 0 being no pain and 10 being the most severe pain ever experienced. Injection with ultrasonography will be performed by a single anesthesiologist. 3 orthopedic surgeons will perform the surgery.

02

Conditions studied

  • Anterior Cruciate Ligament Rupture
  • Femoral Nerve Block
03

In context

Anterior Cruciate Ligament Injuries

625 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 192 are open to participants now.

This study's planned enrollment of 100 is above the median of 56 across 458 interventional studies indexed under Anterior Cruciate Ligament Injuries.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

Chuncheon Sacred Heart Hospital is the lead sponsor of 56 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • individuals who are scheduled to undergo arthroscopic anterior cruciate ligament reconstruction surgery and must be received sufficient explanation about the research prior to surgery and have provided their to participate.

Exclusion criteria

Exclusion Criteria:

  • who require simultaneous surgery for concomitant cartilage injury, medial meniscus tear, and lateral collateral ligament tear.
  • who have previously undergone surgical treatment within the knee joint.
  • who have declined to participate in the research.
  • where medical, surgical, or anesthetic complications occurred during surgery.
  • other cases deemed necessary by the researchers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    FNB

    sono-guided injection with 20ml ropivacaine

    Procedure: Sono-guided injection · Drug: Ropivacaine injection

  • Placebo comparator
    no FNB

    sono-guided injection with 20ml 0.9% saline

    Procedure: Sono-guided injection · Drug: Saline injection

Interventions

  • ProcedureSono-guided injection

    After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.

  • After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.

  • DrugSaline injection

    After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.

06

What researchers measure

Primary outcomes

  1. postoperative pain after 24hours

    VAS (Visual analog scale) measured 24 hours after operation * the unabbreviated scale title: The visual analog scale * the minimum and maximum values: 0, 10 * higher scores mean a worse outcome.

    Time frame: 24hours

Secondary outcomes

  1. postoperative pain after 1, 3, 6, 12, 18, 48 hours

    VAS (Visual analog scale) measured 1, 3, 6, 12, 18, 48 hours after operation * the unabbreviated scale title: The visual analog scale * the minimum and maximum values: 0, 10 * higher scores mean a worse outcome.

    Time frame: 1, 3, 6, 12, 18, 48 hours

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06048874
Lead sponsor
Chuncheon Sacred Heart Hospital
Responsible party
Jung-Taek Hwang (Professor, Chuncheon Sacred Heart Hospital) — Principal investigator
First posted
Sep 21, 2023
Start date
Sep 18, 2023 (estimated)
Primary completion
Sep 18, 2028 (estimated)
Completion
Sep 18, 2028 (estimated)
Last update
Sep 22, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion